DUBLIN – Poxel SA and development partner Sumitomo Dainippon Pharma Co. Ltd. are on track for a regulatory submission of their type 2 diabetes drug, imeglimin, in Japan next year, after the first of three phase III trials delivered a positive result. Two other phase III studies are also due to read out this year, and the partners aim to have the drug on the market by 2021.